A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Status:
Recruiting
Trial end date:
2027-08-03
Target enrollment:
Participant gender:
Summary
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically
amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment
of MDR-TB.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators:
Huashan Hospital No.85 Hospital, Changning, Shanghai, China Shanghai Public Health Clinical Center